Comparative Pharmacology
Head-to-head clinical analysis: EDARBYCLOR versus VISKAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDARBYCLOR versus VISKAZIDE.
EDARBYCLOR vs VISKAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Viskazide is a combination of pindolol (a non-cardioselective beta-blocker with intrinsic sympathomimetic activity) and hydrochlorothiazide (a thiazide diuretic). Pindolol competitively blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule, decreasing sodium and water reabsorption, leading to reduced plasma volume and blood pressure.
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
Oral: 1 tablet (pindolol 10 mg / hydrochlorothiazide 25 mg) once daily; may increase to 2 tablets once daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Terminal elimination half-life is 10-12 hours for the hydrochlorothiazide component and 4-6 hours for pindolol; clinical context: steady-state achieved in 2-3 days for pindolol and 3-5 days for hydrochlorothiazide.
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Renal elimination (approximately 70% unchanged), with the remainder as inactive metabolites; biliary/fecal excretion is minor (<10%).
Category C
Category C
Angiotensin II Receptor Blocker/Thiazide Diuretic Combination
Beta Blocker/Thiazide Diuretic Combination